Physician profile
Brian Wang
NPI 1235591181
$6,590.75
in general payments reported to CMS, 2019-2025
30 companies · $946 in 2025
The $946 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.00 · 2021: $435 · 2022: $1,051 · 2023: $1,992 · 2024: $2,071 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,889.52 |
| Education | $119.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,157.71 | 2021-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $622.64 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $514.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $441.41 | 2021-2025 | Farxiga, Lokelma |
| Mentor Worldwide LLC | $388.47 | 2021-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Mallinckrodt Hospital Products INC. | $344.01 | 2024-2025 | Acthar |
| Ardelyx, INC. | $267.61 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.82 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $239.72 | 2024-2025 | Ozempic, Wegovy, Rivfloza |
| Opko Pharmaceuticals, LLC | $236.87 | 2022-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $223.50 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $200.49 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $196.91 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $191.77 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $185.40 | 2024 | Velphoro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $173.63 | 2022-2024 | Tavneos, Parsabiv, Repatha |
| Akebia Therapeutics INC | $168.57 | 2021-2025 | Vafseo |
| Janssen Pharmaceuticals, INC | $168.48 | 2024 | Xarelto |
| Bard Peripheral Vascular, INC. | $159.05 | 2023 | |
| Alexion Pharmaceuticals, INC. | $116.61 | 2019-2023 | Ultomiris |
| Glaxosmithkline, LLC. | $71.87 | 2022-2023 | Benlysta |
| Daiichi Sankyo INC. | $50.25 | 2022 | |
| Amarin Pharma, INC. | $43.02 | 2021-2022 | |
| Shield Therapeutics INC | $42.48 | 2022-2023 | Accrufer |
| Recor Medical INC | $25.54 | 2024 | Paradise Renal Denervation System |
| Abbvie INC. | $21.91 | 2023 | Teflaro |
| Theratechnologies INC. | $21.68 | 2023 | Trogarzo, Egrifta |
| Arbor Pharmaceuticals, INC. | $19.22 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.15 | 2023 | Keveyis |
| Scpharmaceuticals INC. | $16.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.